Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - A meta-analysis

Journal of Affective Disorders

Volumn 123, Issue 1-3, 2010, Pages 9-16

  Donovan, Mary Rocco ^a   Glue, Paul ^b   Kolluri, Sheela ^c   Emir, Birol ^c  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c PFIZER INC   (United States)

Author keywords

Anxiety; Continuation treatment; Meta analysis; Randomized clinical trial

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; POSTTRAUMATIC STRESS DISORDER SCALE; PRIORITY JOURNAL; RELAPSE; REVIEW; SCORING SYSTEM; SOCIAL PHOBIA; TREATMENT DURATION; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; PERSONALITY ASSESSMENT; PHOBIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 77952103964     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2009.06.021     Document Type: Review

References (53)

1. Allgulander C., Florea I., and Huusom A.K. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol. 9 (2006) 495-505
2. Andrews G., Anderson T.M., Slade T., and Sunderland M. Classification of anxiety and depressive disorders: problems and solutions. Depress Anxiety 25 (2008) 274-281
3. Agresti A. An Introduction to Categorical Data Analysis. Second Edition (2007), Wiley, London, UK
4. Bakker A., van Balkom A.J.L.M., and Stein D. Evidence-based pharmacotherapy of panic disorder. Int. J. Neuropsychopharmacol. 8 (2005) 473-482
5. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Baldwin D.S., den Boer J.A., Kasper S., and Shear M.K. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry 59 (1998) 47-54
6. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Bobes J., Beidel D.C., Ono Y., and Westenberg H.G. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry 59 (1998) 54-60
7. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Borkovec T.D., Rickels K., Stein D.J., and Wittchen H.U. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry 62 (2001) 53-58
8. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Marshall R.D., Nemeroff C.B., Shalev A.Y., and Yehuda R. Consensus statement update on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry 65 (2004) 55-62
9. Bandelow B., Baldwin D.S., Dolberg O.T., Andersen H.F., and Stein D.J. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?. J. Clin. Psychiatry 67 (2006) 1428-1434
10. Bridge J.A., Iyengar S., Salary C.B., Barbe R.P., Birmaher B., Pincus H.A., Ren L., and Brent D.A. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 297 (2007) 1683-1696
11. Clark L.A., and Watson D. Distress and fear disorders: an alternative empirically based taxonomy of the "mood" and "anxiety" disorders. Br. J. Psychiatry 189 (2006) 481-483
12. Cochrane Collobration. Review Manager, Version 5.0 for Windows (2008)
13. Connor K.M., Davidson J.R., Potts N.L., Tupler L.A., Miner C.M., Malik M.L., Book S.W., Colket J.T., and Ferrell F. Discontinuation of clonazepam in the treatment of social phobia. J. Clin. Psychopharmacol. 18 (1998) 373-378
14. Davidson J., Pearlstein T., Londborg P., Brady K.T., Rothbaum B., Bell J., Maddock R., Hegel M.T., and Farfel G. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Focus 1 (2003) 273-281
15. Davidson J.R., Connor K.M., Hertzberg M.A., Weisler R.H., Wilson W.H., and Payne V.M. Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. J. Clin. Psychopharmacol. 25 (2005) 166-169
16. Davidson J.R., Wittchen H.U., Llorca P.M., Erickson J., Detke M., Ball S.G., and Russell J.M. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur. Neuropsychopharmacol. 9 (2008) 673-681
17. Feltner D., Wittchen H.U., Kavoussi R., Brock J., Baldinetti F., and Pande A.C. Long-term efficacy of pregabalin in generalized anxiety disorder. Int. Clin. Psychopharmacol. 23 (2008) 18-28
18. Ferguson J.M., Khan A., Mangano R., Entsuah R., and Tzanis E. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J. Clin. Psychiatry 68 (2007) 58-68
19. Fineberg N., and Gale T.M. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 8 (2005) 107-129
20. Fineberg N.A., Tonnoir B., Lemming O., and Stein D.J. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 17 (2007) 430-439
21. Geddes J.R., Carney S.M., Davies C., Furukawa T.A., Kupfer D.J., Frank E., and Goodwin G.M. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361 (2003) 653-661
22. Geller D.A., Biederman J., Stewart S.E., Mullin B., Farrell C., Wagner K.D., Emslie G., and Carpenter D. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?. J. Child Adolesc. Psychopharmacol. 13 (2003) S19-29
23. GlaxoSmithKline Clinical Trial Register (http://ctrgskcouk/Summary/paroxetine/studylistasp) Study MY-1050/BRL-029060/1/CPMS-222 (PAR 222).
24. GlaxoSmithKline Clinical Trial Register (http://ctrgskcouk/Summary/paroxetine/studylistasp) Study MY-1053/BRL-029060/CPMS-127.
25. Guy W. ECDEU Assessment Manual for Psychopharmacology (1976), US Department of Health, Education and Welfare, Washington DC 218-222
26. Higgins J.P.T., and Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 500 [updated February 2008] The Cochrane Collaboration (2008). http://www.cochrane-handbook.org www.cochrane-handbook.org
27. Hollander E., Allen A., Steiner M., Wheadon D.E., Oakes R., Burnham D.B., and Paroxetine OCD Study Group. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J. Clin. Psychiatry 64 (2003) 1113-1121
28. Kamijima K., Kuboki T., Kumano H., Burt T., Cohen G., Arano I., and Hamasaki T.A. Placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int. Clin. Psychopharmacol. 20 (2005) 265-273
29. Kessler R.C., Nelson C.B., McGonagle K.A., Liu J., Swartz M., and Blazer D.G. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br. J. Psychiatry Suppl. 30 (1996) 17-30
30. Khan A., Kolts R.L., Rapaport M.H., Krishnan K.R., Brodhead A.E., and Browns W.A. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol. Med. 35 (2005) 743-749
31. Koran L.M., Hackett E., Rubin A., Wolkow R., and Robinson D. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am. J. Psychiatry 159 (2002) 88-95
32. Laupacis A., Sackett D.L., and Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. N. Engl. J. Med. 318 (1988) 1728-1733
33. Martenyi F., Brown E.B., Zhang H., Koke S.C., and Prakash A. Fluoxetine v placebo in prevention of relapse in post-traumatic stress disorder. Br. J. Psychiatry 181 (2002) 315-320
34. Mavissakalian M., and Perel J.M. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch. Gen. Psychiatry 49 (1992) 318-323
35. Mavissakalian M.R., and Perel J.M. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch. Gen. Psychiatry 56 (1999) 821-827
36. Michelson D., Pollack M., Lydiard R.B., Tamura R., Tepner R., and Tollefson G. Continuing treatment of panic disorder after acute response: randomized, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br. J. Psychiatry 174 (1999) 213-218
37. Montgomery S.A., Nil R., Dürr-Pal N., Loft H., and Boulenger J.P. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J. Clin. Psychiatry 66 (2005) 1270-1278
38. Mundo E., Bareggi S.R., Pirola R., Bellodi L., and Smeraldi E. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J. Clin. Psychopharmacol. 17 (1997) 4-10
39. Pato M.T., Hill J.L., and Murphy D.L. A clomipramine dosage reduction study in the course of the long-term treatment of obsessive-compulsive patients. Psychopharmacol. Bull. 26 (1990) 211-214
40. Rapaport M.H., Wolkow R., Rubin A., Hackett E., Pollack M., and Ota K.Y. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr. Scand. 104 (2001) 289-298
41. Romano S., Goodman W., Tamura R., and Gonzales J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J. Clin. Psychopharmacol. 21 (2001) 46-52
42. Schweizer E., and Rickels K. Placebo response in generalized anxiety: its effect on the outcome of clinical trials. J. Clin. Psychiatry 58 (1997) 30-38
43. Solvason H.B., Ernst H., and Roth W. Predictors of response in anxiety disorders. Psychiatr. Clin. North Am. 26 (2003) 411-433
44. Stein D.J., Ipser J.C., and van Balkom A.J. Pharmacotherapy for social anxiety disorder. Cochrane Database of Systematic Reviews (2000) CD001206
45. Stein D.J., Versiani M., Hair T., and Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch. Gen. Psychiatry 59 (2002) 1111-1118
46. Stein D.J., Ipser J.C., and Seedat S. Pharmacotherapy for post-traumatic stress disorder. Cochrane Database of Systematic Reviews (2006) CD002795
47. Stein D.J., Baldwin D.S., Dolberg O.T., Despiegel N., and Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J. Clin. Psychiatry 67 (2006) 1741-1746
48. Stein M.B., Chartier M.J., Hazen A.L., Kroft C.D., Chale R.A., Coté D., and Walker J.R. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J. Clin. Psychopharmacol. 16 (1996) 218-222
49. Stocchi F., Nordera G., Jokinen R.H., Lepola U.M., Hewett K., Bryson H., Iyengar M.K., and Paroxetine Generalized Anxiety Disorder Study Team. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry 64 (2003) 250-258
50. Struzik L., Vermani M., Coonerty-Femiano A., and Katzman M.A. Treatments for generalized anxiety disorder. Expert. Rev. Neurother. 4 (2004) 285-294
51. Tukey J.W. Exploratory Data Analysis (1974), Addison-Wesley, Reading, Mass
52. Walker J.R., Van Ameringen M.A., Swinson R., Bowen R.C., Chokka P.R., Goldner E., Johnston D.C., Lavallie Y.J., Nandy S., Pecknold J.C., Hadrava V., and Lane R.M. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J. Clin. Psychopharmacol. 20 (2000) 636-644
53. Zohar J., and Westenberg H.G.M. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psych. Scand. 101 (2000) 39-49